Carrier Screening and Diagnosis for Spinal Muscular Atrophy Using Droplet Digital PCR Versus MLPA: Analytical Validation and Early Test Outcome
Genetic Testing and Molecular Biomarkers · 2024
DOI: 10.1089/gtmb.2023.0073 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Genetic Testing and Molecular Biomarkers, 2024. Verfasst von Dolat Singh Shekhawat und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, All India Institute of Medical Science Jodhpur, Jodhpur, Rajasthan, India. Hauptthemen laut MEDLINE: Muscular Atrophy, Spinal, Survival of Motor Neuron 1 Protein, Survival of Motor Neuron 2 Protein, DNA Copy Number Variations. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular life-threatening disorder. Owing to high carrier frequency, population-wide SMA screening to quantify the copy number of SMN gene is recommended by American College of Medical Genetics and Genomics. An accurate, reliable, short runaround time and cost-effective method may be helpful in mass population screening for SMA.
Methods
Multiplex ligation-dependent probe amplification (MLPA) is a gold standard to estimate the copy number variation (CNV) for SMN1 and SMN2 genes. In this study, we validated droplet digital polymerase chain reaction (ddPCR) for the determination of CNV for both SMN1 and SMN2 exon 7 for a diagnostic purpose. In total, 66 clinical samples were tested using ddPCR, and results were compared with the MLPA as a reference test.
Results
For all samples, CNV for SMN1 and SMN2 exon 7 was consentaneous between ddPCR and MLPA test results (κ = 1.000, p < 0.0001). In addition, ddPCR also showed a significant acceptable degree of test repeatability, coefficient of variation < 4%. Conclusion: ddPCR is expected to be utilitarian for CNV detection for carrier screening and diagnosis of SMA. ddPCR test results for CNV detection for SMN1/SMN2 exon 7 are concordant with the gold standard. ddPCR is a more cost-effective and time-saving diagnostic test for SMA than MLPA. Furthermore, it can be used for population-wide carrier screening for SMA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, All India Institute of Medical Science Jodhpur, Jodhpur, Rajasthan, India.
- Department of Medical Genetics, All India Institute of Medical Science Jodhpur, Jodhpur, Rajasthan, India.
- NIDAN Kendra, Genetic Laboratory, All India Institute of Medical Science Jodhpur, Jodhpur, Rajasthan, India.
- Department of Anatomy, All India Institute of Medical Science Jodhpur, Jodhpur, Rajasthan, India.
- Department of Obstetrics & Gynaecology, All India Institute of Medical Science Jodhpur, Jodhpur, Rajasthan, India.
ORCID-Profile: Dolat Singh Shekhawat
Zitieren
APA
Shekhawat, D. S., Didel, S., Dixit, S. G., Singh, P., & Singh, K. (2024). Carrier Screening and Diagnosis for Spinal Muscular Atrophy Using Droplet Digital PCR Versus MLPA: Analytical Validation and Early Test Outcome. Genetic Testing and Molecular Biomarkers. https://doi.org/10.1089/gtmb.2023.0073
Vancouver
Shekhawat DS, Didel S, Dixit SG, Singh P, Singh K. Carrier Screening and Diagnosis for Spinal Muscular Atrophy Using Droplet Digital PCR Versus MLPA: Analytical Validation and Early Test Outcome. Genetic Testing and Molecular Biomarkers. 2024. doi:10.1089/gtmb.2023.0073
BibTeX
@article{Shekhawat2024,
author = {Shekhawat, Dolat Singh and Didel, Siyaram and Dixit, Shilpi Gupta and Singh, Pratibha and Singh, Kuldeep},
title = {Carrier Screening and Diagnosis for Spinal Muscular Atrophy Using Droplet Digital PCR Versus MLPA: Analytical Validation and Early Test Outcome},
journal = {Genetic Testing and Molecular Biomarkers},
year = {2024},
doi = {10.1089/gtmb.2023.0073}
}
EUVIMED